• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

First Generic Equivalent to Tamiflu Capsules Launched in US


December 12, 2016

Alvogen (Pine Brook, NJ) has launched the first generic equivalent to Roche's Tamiflu (oseltamivir phosphate) capsules in the United States.   Alvogen reports that it expects the capsules "to deliver significant savings for patients and health providers of up to $500 million during this upcoming season." The product is available in three strengths (30 mg, 45 mg and 75 mg).   A consortium of investors, led by CVC Capital Partners and including Singapore-based investment company Temasek and Vatera Healthcare Partners, acquired a majority stake in Alvogen in June 2015. 

Related Videos